Article Figures & Data
Figures
- Fig 1.
Patient disposition with numbers of patients enrolled (n = 279) and randomized (n = 274) to undergo 2 identical MR imaging examinations with gadoterate meglumine followed by gadobutrol (arm 1) or with gadobutrol followed by gadoterate meglumine (arm 2). A total of 268 patients received the first contrast agent injection, and 249 patients completed the study with the 2 examinations performed.
- Fig 2.
Rate of patients with overall lesion visualization and characterization scored good/excellent or poor/fair. The bar graph shows the rate of patients with overall lesion visualization and characterization scored good/excellent or poor/fair according to each contrast agent and each off-site reader (n = 234 patients for all readers).
- Fig 3.
A 46-year-old woman with glioblastoma. T1 spin-echo images (1.5T) after administration of 0.1 mmol/kg of gadoterate meglumine (A) and gadobutrol (B) show an approximate 65-mm lesion. The time between the 2 MR imaging examinations was 7 days. Lesion visualization and characterization were scored as excellent by all 3 blinded readers. The enhancing rim of the lesion is clearly seen on both examinations.
- Fig 4.
A 74-year-old man with a high-grade glioma. T1 spin-echo images (1.5T) after administration of 0.1 mmol/kg of gadoterate meglumine (A) and gadobutrol (B) show an approximate 30-mm mass. The time between the 2 MR imaging examinations was 8 days. Lesion visualization and characterization were scored as excellent by all 3 blinded readers. The mass is clearly seen on both examinations and shows no difference in contrast enhancement.
- Fig 5.
Classification in preference subgroups for lesion border delineation (A), lesion internal morphology (B), and degree of contrast enhancement (C). The bar graphs show the rate of patients classified in preference subgroups for lesion border delineation (A), lesion internal morphology (B), and degree of contrast enhancement (C), according to each off-site reader (n = 234 patients for all readers; n = 231 patients for reader 1; n = 233 patients for reader 2; n = 232 patients for reader 3), with P > .1 for the 3 end points for all readers (Wilcoxon signed rank test).
Tables
Signal-intensity measurements
LS Meana (SE) LS Meana Difference (95% CI) P Value Gadoterate Meglumine Gadobutrol SNR Reader 1 266.79 (5.00) 281.41 (5.02) −14.61 (−22.77 to −6.46) <.001 Reader 2 157.21 (4.75) 167.46 (4.75) −10.26 (−21.58 to 1.07) .076 Reader 3 192.94 (4.98) 203.35 (4.97) −10.41 (−22.75 to 1.93) .098 CNR Reader 1 117.22 (7.83) 140.84 (7.84) −23.62 (−33.25 to −13.99) <.001 Reader 2 64.59 (4.19) 72.02 (4.19) −7.42 (−14.87 to 0.03) .051 Reader 3 82.96 (5.16) 96.44 (5.15) −13.48 (−23.43 to −3.54) .008 Percentage enhancement Reader 1 107.61 (3.93) 121.72 (3.93) −14.12 (−18.38 to −9.85) <.001 Reader 2 93.90 (3.63) 107.12 (3.63) −13.22 (−17.28 to −9.16) <.001 Reader 3 98.82 (3.77) 114.47 (3.76) −15.66 (−20.52 to −10.79) <.001 Note:—SE indicates standard error.
↵a LS means are the means controlled for covariates of the model.
